VP of Application Science, BioPharmics Division
Ann has a PhD in Microbiology and Cell Biology from the University of Illinois, followed by work in Biochemistry as a Helen Hay Whitney post-doctoral fellow at the University of California, San Francisco (UCSF).
She moved to small biopharma beginning with MetaXen in 1997, leading many aspects of biological research and complex assay development across multiple projects. Ann’s research focus shifted to the causal linkages between molecular structure and human pharmacology.
Her research spanned both the academic environment of UCSF and the applied realm within BioPharmics LLC since its founding in 1998. Ann has a deep understanding of how to solve challenging problems in pre-clinical pharmaceutical discovery using sophisticated computational approaches for ligand- and structure-based predictive modeling. BioPharmics LLC became the BioPharmics Division of Optibrium in August 2023.
The Chemical Information & Computer Applications Group (CICAG) and Biological & Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry are once again organising a conference to present the current advances in AI and machine learning in Chemistry.
The joint ISSX/JSSX meeting is for researchers looking to gain a deeper understanding of drug metabolism and pharmacokinetics.
Key appointment brings extensive software commercial experience to drive global growth
